BIOMAT Database Logo BIOMAT Database Logo

Effect of topical ophthalmic dorzolamide(2%)-timolol(0.5%) solution and ointment on intraocular pressure in normal horses. 2015

Kyle L Tofflemire, and Elizabeth M Whitley, and Allison M Flinn, and Valerie L Dufour, and Gil Ben-Shlomo, and Rachel A Allbaugh, and Angela N Griggs, and Chimene S Peterson, and David R Whitley
Department of Veterinary Clinical Sciences, Iowa State University College of Veterinary Medicine, Ames, IA, 50011, USA.

OBJECTIVE To compare the effect of commercially available solution and compounded ointment formulations of dorzolamide(2%)-timolol(0.5%) on intraocular pressure (IOP) of normal horses. METHODS Eighteen clinically normal horses. METHODS A randomized, masked prospective design was used with horses divided into two equal groups. One eye of each horse was selected for topical ophthalmic treatment with either 0.2 mL of dorzolamide(2%)-timolol(0.5%) solution or 0.2 g of dorzolamide(2%)-timolol(0.5%) ointment every 12 h for 5 days. The contralateral eye of horses in both groups was untreated. Rebound tonometry was performed every 6 h starting 2 days prior to and ending 2 days after the treatment period. RESULTS The mean IOP reduction in eyes treated with the solution or ointment formulations was 13%. Untreated eyes in both groups experienced a lesser but still statistically significant reduction in IOP. The IOP values did not return to baseline within 48 h of the last treatment. CONCLUSIONS The commercially available solution and compounded ointment formulations of ophthalmic dorzolamide(2%)-timolol(0.5%) had similar effects on IOP in normal horses. Persistent IOP reduction following cessation of treatment may indicate prolonged drug effect or acclimation of horses to tonometry.

UI MeSH Term Description Entries
D007429 Intraocular Pressure The pressure of the fluids in the eye. Ocular Tension,Intraocular Pressures,Ocular Tensions,Pressure, Intraocular,Pressures, Intraocular,Tension, Ocular,Tensions, Ocular
D008297 Male Males
D009824 Ointments Semisolid preparations used topically for protective emollient effects or as a vehicle for local administration of medications. Ointment bases are various mixtures of fats, waxes, animal and plant oils and solid and liquid hydrocarbons. Ointment,Paste,Pastes,Salve,Unguent,Salves,Skin Ointment,Unguents,Ointment, Skin
D009883 Ophthalmic Solutions Sterile solutions that are intended for instillation into the eye. It does not include solutions for cleaning eyeglasses or CONTACT LENS SOLUTIONS. Eye Drop,Eyedrop,Eyedrops,Ophthalmic Solution,Eye Drops,Drop, Eye,Drops, Eye,Solution, Ophthalmic,Solutions, Ophthalmic
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D005260 Female Females
D006736 Horses Large, hoofed mammals of the family EQUIDAE. Horses are active day and night with most of the day spent seeking and consuming food. Feeding peaks occur in the early morning and late afternoon, and there are several daily periods of rest. Equus caballus,Equus przewalskii,Horse, Domestic,Domestic Horse,Domestic Horses,Horse,Horses, Domestic
D000319 Adrenergic beta-Antagonists Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. Adrenergic beta-Antagonist,Adrenergic beta-Receptor Blockader,Adrenergic beta-Receptor Blockaders,beta-Adrenergic Antagonist,beta-Adrenergic Blocker,beta-Adrenergic Blocking Agent,beta-Adrenergic Blocking Agents,beta-Adrenergic Receptor Blockader,beta-Adrenergic Receptor Blockaders,beta-Adrenoceptor Antagonist,beta-Blockers, Adrenergic,beta-Adrenergic Antagonists,beta-Adrenergic Blockers,beta-Adrenoceptor Antagonists,Adrenergic beta Antagonist,Adrenergic beta Antagonists,Adrenergic beta Receptor Blockader,Adrenergic beta Receptor Blockaders,Adrenergic beta-Blockers,Agent, beta-Adrenergic Blocking,Agents, beta-Adrenergic Blocking,Antagonist, beta-Adrenergic,Antagonist, beta-Adrenoceptor,Antagonists, beta-Adrenergic,Antagonists, beta-Adrenoceptor,Blockader, Adrenergic beta-Receptor,Blockader, beta-Adrenergic Receptor,Blockaders, Adrenergic beta-Receptor,Blockaders, beta-Adrenergic Receptor,Blocker, beta-Adrenergic,Blockers, beta-Adrenergic,Blocking Agent, beta-Adrenergic,Blocking Agents, beta-Adrenergic,Receptor Blockader, beta-Adrenergic,Receptor Blockaders, beta-Adrenergic,beta Adrenergic Antagonist,beta Adrenergic Antagonists,beta Adrenergic Blocker,beta Adrenergic Blockers,beta Adrenergic Blocking Agent,beta Adrenergic Blocking Agents,beta Adrenergic Receptor Blockader,beta Adrenergic Receptor Blockaders,beta Adrenoceptor Antagonist,beta Adrenoceptor Antagonists,beta Blockers, Adrenergic,beta-Antagonist, Adrenergic,beta-Antagonists, Adrenergic,beta-Receptor Blockader, Adrenergic,beta-Receptor Blockaders, Adrenergic
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013449 Sulfonamides A group of compounds that contain the structure SO2NH2. Sulfonamide,Sulfonamide Mixture,Sulfonamide Mixtures,Mixture, Sulfonamide,Mixtures, Sulfonamide

Related Publications

Kyle L Tofflemire, and Elizabeth M Whitley, and Allison M Flinn, and Valerie L Dufour, and Gil Ben-Shlomo, and Rachel A Allbaugh, and Angela N Griggs, and Chimene S Peterson, and David R Whitley
24-hour control of intraocular pressure with 2% dorzolamide/0.5% timolol fixed-combination ophthalmic solution in open-angle glaucoma.
August 2008, Current medical research and opinion,
Kyle L Tofflemire, and Elizabeth M Whitley, and Allison M Flinn, and Valerie L Dufour, and Gil Ben-Shlomo, and Rachel A Allbaugh, and Angela N Griggs, and Chimene S Peterson, and David R Whitley
Effects of topical 2% dorzolamide hydrochloride alone and in combination with 0.5% timolol maleate on intraocular pressure in normal feline eyes.
January 2007, Veterinary ophthalmology,
Kyle L Tofflemire, and Elizabeth M Whitley, and Allison M Flinn, and Valerie L Dufour, and Gil Ben-Shlomo, and Rachel A Allbaugh, and Angela N Griggs, and Chimene S Peterson, and David R Whitley
Effect of topical ophthalmic latanoprost on intraocular pressure in normal horses.
January 2002, Veterinary therapeutics : research in applied veterinary medicine,
Kyle L Tofflemire, and Elizabeth M Whitley, and Allison M Flinn, and Valerie L Dufour, and Gil Ben-Shlomo, and Rachel A Allbaugh, and Angela N Griggs, and Chimene S Peterson, and David R Whitley
Effect of topical administration of 2% dorzlamide hydrochloride or 2% dorzlamide hydrochloride-0.5% timolol maleate on intraocular pressure in clinically normal horses.
May 2001, American journal of veterinary research,
Kyle L Tofflemire, and Elizabeth M Whitley, and Allison M Flinn, and Valerie L Dufour, and Gil Ben-Shlomo, and Rachel A Allbaugh, and Angela N Griggs, and Chimene S Peterson, and David R Whitley
Topical dorzolamide 2%/timolol 0.5% ophthalmic solution: a review of its use in the treatment of glaucoma and ocular hypertension.
January 2006, Drugs & aging,
Kyle L Tofflemire, and Elizabeth M Whitley, and Allison M Flinn, and Valerie L Dufour, and Gil Ben-Shlomo, and Rachel A Allbaugh, and Angela N Griggs, and Chimene S Peterson, and David R Whitley
Intraocular pressure decrease in normal volunteers following timolol ophthalmic solution.
June 1976, Investigative ophthalmology,
Kyle L Tofflemire, and Elizabeth M Whitley, and Allison M Flinn, and Valerie L Dufour, and Gil Ben-Shlomo, and Rachel A Allbaugh, and Angela N Griggs, and Chimene S Peterson, and David R Whitley
Effect of Topically Applied 0.5% Apraclonidine Versus 0.5% Timolol Maleate on Intraocular Pressure of Healthy Horses.
April 2022, Journal of equine veterinary science,
Kyle L Tofflemire, and Elizabeth M Whitley, and Allison M Flinn, and Valerie L Dufour, and Gil Ben-Shlomo, and Rachel A Allbaugh, and Angela N Griggs, and Chimene S Peterson, and David R Whitley
Effect of 3 years of treatment with a dorzolamide/timolol (1%/0.5%) combination on intraocular pressure.
January 2014, Clinical ophthalmology (Auckland, N.Z.),
Kyle L Tofflemire, and Elizabeth M Whitley, and Allison M Flinn, and Valerie L Dufour, and Gil Ben-Shlomo, and Rachel A Allbaugh, and Angela N Griggs, and Chimene S Peterson, and David R Whitley
Effects of topical 0.5% levobunolol alone or in association with 2% dorzolamide compared with a fixed combination of 0.5% timolol and 2% dorzolamide on intraocular pressure and heart rate in dogs without glaucoma.
January 2010, Veterinary therapeutics : research in applied veterinary medicine,
Kyle L Tofflemire, and Elizabeth M Whitley, and Allison M Flinn, and Valerie L Dufour, and Gil Ben-Shlomo, and Rachel A Allbaugh, and Angela N Griggs, and Chimene S Peterson, and David R Whitley
The influence of diclofenac ophthalmic solution on the intraocular pressure-lowering effect of topical 0.5% timolol and 0.005% latanoprost in primary open-angle glaucoma patients.
November 2005, Experimental eye research,
Copied contents to your clipboard!